

DAFTAR PUSTAKA

1. Budihusodo U. Karsinoma Hati. Buku Ajar Ilmu Penyakit Dalam Edisi VII. Jakarta : PIPInterna, 2024.
2. Hasan I, Loho I, Setiawan P, Purnomo H. *Konsensus Nasional Terapi Sistemik Karsinoma Sel Hati Di Indonesia.*; 2021.
3. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. *Hepatology*. 2021;73(S1):4-13. doi:10.1002/hep.31288
4. Bachtiar R, Parewangi ML, Akil F, Daud NA, Kusuma SH, Rifai A. Perubahan Paradigma pada Strategi Penanganan Karsinoma Hepatoseluler: Systematic Review. *UMI Med J*. 2022;7(1):59-71. doi:10.33096/umj.v7i1.150
5. Aprilicia G, Bantas K, Syarif S, Kalista KF. Evaluasi Perbandingan Serum Alfa-Fetoprotein pada Pasien Karsinoma Hepatoseluler dengan Etiologi Non-Viral. *J Penyakit Dalam Indones*. 2021;8(1):37. doi:10.7454/jpdi.v8i1.566
6. Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. *J Res Med Sci*. 2019;24(1):86.
7. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. *Cancer Interdiscip Int J Am Cancer Soc*. 1996;77(11):2217-2222.
8. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxí A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology*. 2010;51(4):1274-1283. doi:10.1002/hep.23485
9. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher CH, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. *Gut*. 2001;48(1):103-109.
10. O WH. *Guidelines on Hepatitis B and C Testing*. Vol 66.; 2017. <https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1%0Ahttp://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf?sequence=1%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/28742301%0Ahttp://www>



.ncbi.nlm.nih.gov/pubmed/2874

11. Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. *World J Gastroenterol*. 2020;26(33):5022-5049. doi:10.3748/wjg.v26.i33.5022
12. Calderon-Martinez E, Landazuri-Navas S, Vilchez E, et al. Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. *J Clin Med Res*. 2023;15(4):200-207. doi:10.14740/jocmr4902
13. Singal AG, Llovet JM, Yarchoan M, et al. *AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma*; 2023. doi:10.1097/hep.0000000000000466
14. Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. *World J Hepatol*. 2019;11(1):1-18. doi:10.4254/wjh.v11.i1.1
15. Perhimpunan Peneliti Hati Indonesia. Epidemiologi dan Faktor Risiko Kanker Sel Hati. *Konsensus Nas Penatalaksanaan Karsinoma Sel Hati*. Published online 2017:7-11.
16. Valle Tovo C, de Mattos AZ, Coral GP, et al. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. *World J Gastroenterol*. 2023;29(2):343-356. doi:10.3748/wjg.v29.i2.343
17. Armandi A, Caviglia GP, Abdulle A, et al. Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. *Cancers (Basel)*. 2023;15(6). doi:10.3390/cancers15061659
18. Gao Y, Zhu R, Dong J, Li Z. Pathogenesis of NAFLD-Related Hepatocellular Carcinoma : An Up-to-Date Review. 2023;(March):347-356.
19. Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? *Int J Biol Sci*. 2022;18(2):536-551. doi:10.7150/ijbs.64537



Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on management of hepatocellular carcinoma: a 2017 update. *Hepatol Int*.

2017;11(4):317-370. doi:10.1007/s12072-017-9799-9

21. Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. *Cells*. 2020;9(6):1-27. doi:10.3390/cells9061370
22. Nakatsuka T, Tateishi R. HCC incidence is decreasing in Korea but increasing in elderly Early changes in biomarkers predict HBsAg response Baveno-VII predicts decompensation in cACLD Development and prognosis of hepatocellular carcinoma in patients with diabetes. *Clin Mol Hepatol*. 2023;29(1):51-64. <https://doi.org/10.3350/cmh.2022.0095>
23. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol*. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
24. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol*. 2022;76(3):681-693. doi:10.1016/j.jhep.2021.11.018
25. Colleoni M, Bajetta E, Nelli P, et al. Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the national cancer institute of milan. *Ann Oncol*. 1993;4(6):489-493. doi:10.1093/oxfordjournals.annonc.a058560
26. Le DC, Nguyen TM, Nguyen DH, Nguyen DT, Nguyen LTM. Survival Outcome and Prognostic Factors Among Patients With Hepatocellular Carcinoma: A Hospital-Based Study. *Clin Med Insights Oncol*. 2023;17. doi:10.1177/11795549231178171
27. Han KH, Kim DY, Park JY, et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: A 15-year prospective study. *J Clin Gastroenterol*. 2013;47(6):538-544. doi:10.1097/MCG.0b013e3182755c13
28. Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hilar carcinoma : A single center 14 years experience from China. *Med ites*). 2019;98(4). doi:10.1097/MD.00000000000014070

